This is the main reason this disease remains undertreated despite significant therapeutic progress made by the application of drugs based on monoclonal antibodies against the calcitonin gene-related peptide (CGRP) and the antagonists of and antibodies against its receptor in migraine prevention and therapy [1,2]. This evidence concerns the gene CALCA and migraine disorder.